Recombinant CD Proteins for CAR-T, CAR-NK & Immunology Research
BioCrest Sci supplies recombinant cluster of differentiation (CD) proteins for immune-cell profiling, therapeutic antibody discovery, CAR-T and CAR-NK target research, flow cytometry controls, and binding assays. The portfolio includes human and animal species, multiple expression systems, and formats such as His-tagged, Fc-tagged, Avi-tagged, biotinylated, and tag-free proteins.
What Are CD Proteins?
CD proteins are cell-surface or immune-associated molecules used to identify and characterize leukocyte populations. Because many CD antigens also function as receptors, co-receptors, adhesion molecules, or therapeutic targets, recombinant CD proteins are widely used in immunology, oncology, cell therapy, and biologic drug development.
CD Proteins by Research Area
T Cell Markers and Co-Stimulatory Molecules
CD3, CD4, CD8, CD27, CD28, CD40L, and related proteins support T-cell phenotyping, antibody validation, receptor-ligand studies, and functional assay development.
B Cell and Hematologic Targets
CD19, CD20, CD22, CD37, CD38, and BCMA/CD269 are important targets for B-cell biology, hematologic oncology, bispecific antibodies, and engineered cell therapies.
Myeloid and Innate Immune Markers
CD11b, CD14, CD33, CD47, CD68, and related targets are used in monocyte, macrophage, dendritic-cell, and tumor-microenvironment research.
CAR-T and CAR-NK Target Proteins
CAR-T and CAR-NK programs require well-characterized target antigens for antibody screening, CAR binding studies, assay development, and specificity testing. Commonly investigated targets include CD19, CD20, CD22, BCMA/CD269, CD33, CD123, HER2/ERBB2, GPC3, and Claudin 18.2. BioCrest Sci offers soluble extracellular domains and selected active, biotinylated, Avi-tagged, Fc-tagged, and transmembrane-protein formats to support different assay designs.
For broader target discovery, visit Featured Protein Targets, Immune Checkpoint Proteins, and Avi-Tagged Proteins.
Research Applications
- CAR-T and CAR-NK target-antigen binding and specificity studies
- Therapeutic antibody screening and characterization
- SPR, BLI, ELISA, and receptor-ligand binding assays
- Flow cytometry antibody validation and immunophenotyping
- Cell sorting, assay calibration, and analytical method development
How to Choose a Recombinant CD Protein
Select the species, extracellular-domain boundaries, expression system, tag, oligomeric state, and activity level that match the assay. Mammalian-expressed proteins may be preferred when native-like glycosylation is important; biotinylated or Avi-tagged formats can simplify oriented immobilization; Fc-tagged proteins may support avidity-dependent assays. Always review the individual product datasheet for sequence, purity, tag position, and validated applications.
Frequently Asked Questions
Which CD proteins are commonly used in CAR-T research?
Frequently studied targets include CD19, CD20, CD22, BCMA/CD269, CD33, and CD123. The best target and protein format depend on the cell therapy program and assay design.
Can recombinant CD proteins be used for SPR or BLI?
Yes. Soluble extracellular domains, Fc-tagged proteins, and site-specifically biotinylated proteins are commonly used for SPR and BLI. Confirm compatibility using the product-specific sequence and tag information.
Are all CD proteins biologically active?
No. Activity and validation methods are product-specific. Choose an active protein when functional activity is required and consult the individual datasheet before use.